Interleukin 31 Inhibitors Market Size, Share, and Industry Analysis, By Drug (Nemolizumab and Others), By Indication (Atopic Dermatitis, Prurigo Nodularis, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Interleukin 31 (IL 31) belongs to the group of IL-6 cytokines, which are characterized by its pro-inflammatory properties. It plays a crucial role in various diseases, particularly those involving inflammation and immune responses. IL-31 has a significant role in inflammation to fight off infections or injuries. However, the dysregulation of IL-31 signaling leading to chronic inflammation can also lead to the development of diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease. IL-31 has also been implicated in skin diseases such as atopic dermatitis, psoriasis, and pruritus.

Various studies have shown that elevated levels of IL-31 contribute to the symptoms of itching and inflammation in atopic dermatitis patients. Additionally, studies have shown that IL-31 is involved in the pathogenesis of certain types of cancer, such as cutaneous T-cell lymphoma and breast cancer. Consequently, blocking is considered to reduce the itchiness and inflammation associated with atopic dermatitis and other diseases.

The market for IL 31 inhibitors is expected to grow significantly in the coming years. The market growth can be attributed to the increasing understanding of the role of IL-31 in various inflammatory skin diseases and the demand for effective treatments targeting IL-31. Additionally, the R&D initiatives to develop antibodies against IL-31 and a rising number of clinical trials are expected to result in product launches in the near future. Nemolizumab is the only marketed IL-31 inhibitor. Currently, it's only available in Japan, and approvals in the U.S. and Europe are expected in 2024.

Furthermore, collaboration initiatives between pharmaceutical companies to develop novel drugs targeting the IL-31 are expected to increase the number of new product launches. Moreover, the demand for effective drugs against pruritus associated with various skin conditions is expected to increase the adoption of IL-31 inhibitors in the coming years.

• For instance, in December 2019, Numab Therapeutics AG and 3SBio's Subsidiary Sunshine Guojian collaborated to develop multi-specific antibodies for various targets, including IL-31. These collaborations are expected to drive new product launches in the coming years.

Segmentation

Key Insights

The report covers the following key insights

• Prevalence of Key Diseases, By Key Country/Region, 2023
• Pipeline Analysis
• Key Industry Developments: Mergers, Acquisitions, and Partnerships
• Impact of COVID-19 on the Market

Analysis by Indication

Based on indication, the market is classified into atopic dermatitis, prurigo nodularis, and others. The atopic dermatitis segment generated a significant market share in 2023. The IL-31 inhibitor is currently approved for atopic dermatitis. Furthermore, solid clinical evidence of IL-31 inhibitors in atopic dermatitis and the pipeline drugs for atopic dermatitis targeting IL-31, and the rising prevalence of atopic dermatitis are expected to propel the market growth in the near future.

• According to an article published in the British Journal of Dermatology in December 2023, around 204.05 million people are affected by atopic dermatitis across the globe. Such a high prevalence of atopic dermatitis is expected to drive the iL-31 inhibitor market in the coming years to control the pruritus associated with the condition.

The prurigo nodularis segment is projected to experience considerable growth in the upcoming years due to the growing number of clinical studies. Moreover, the expected approval of nemolizumab for prurigo nodularis is expected to boost the revenue of the segment in the coming years.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific accounted for a dominant market share in 2023. The current approval of Il-31 inhibitors in the region contributes to the dominance of the region in the market. The high prevalence of atopic dermatitis in countries such as Japan is expected to increase the adoption of IL-31, making it a potential market in terms of the global scenario.

• For instance, according to the article published in PLUS ONE in May 2022, around 10.0% of Japan's population is affected by asthma and atopic dermatitis. Such high prevalence and availability of IL 31 inhibitors are expected to drive the market in the region.

Europe is expected to witness considerable growth in the market due to the rising number of clinical trials and increasing awareness about skin conditions in the region. Moreover, the presence of major players in the region and expected drug approvals against IL-31 in the near future is expected to drive the region's growth significantly in the coming years.

• For instance, GALDERMA announced filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and moderate-to-severe atopic dermatitis in Switzerland and the U.K.

Key Players Covered

The report includes key players, such as Numab Therapeutics AG, GALDERMA, and Chugai Pharmaceutical Co., Ltd.

Key Industry Developments

• In February 2024, GALDERMA announced regulatory filing acceptance for nemolizumab for the treatment of atopic dermatitis and prurigo nodularis in the U.S. and Europe.
• In October 2023, Numab Therapeutics AG started Phase 1a/b clinical trial dosing in the patients for NM26 bi-specific antibodies against IL-4Rα and IL-31 to control moderate-to-severe atopic dermatitis (AD).
• In March 2022, Chugai Pharmaceutical Co., Ltd. obtained regulatory approval from the Ministry of Health, Labour, and Welfare for the Mitchga to treat itching associated with atopic dermatitis. It is an anti-IL-31 receptor A humanized monoclonal antibody subcutaneous Injection.